APOC3 Mutation, Serum Triglyceride Concentrations, and Coronary Heart Disease

Recent decades have witnessed an increasing awareness of the importance of lowering triglyceride concentrations in conjunction with lowering LDL cholesterol (LDL-C) 3 to achieve optimal reduction of the risk for coronary heart disease (CHD). Historically, LDL-C was the only target of pharmacologic therapy in CHD prevention. Thus the first Adult Treatment Panel (ATP I) of the National Cholesterol Education Program published in 1988 used only LDL-C cutoffs as guidelines. Since then, there have been incremental changes with regard to the importance of lowering triglyceride concentrations in addition to LDL-C. In ATP II, triglyceride was still not recognized as an independent risk factor, but the upper limit considered healthy for triglycerides was lowered from 250 to 200 mg/dL. ATP II

Перевод пока недоступен